These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1252 related articles for article (PubMed ID: 29137653)

  • 21. PAM50 intrinsic subtypes, risk of recurrence score and breast cancer survival in HIV-positive and HIV-negative patients-a South African cohort study.
    Phakathi B; Dix-Peek T; Van Den Berg E; Dickens C; Nietz S; Cubasch H; Joffe M; Neugut AI; Jacobson JS; Ruff P; Duarte R
    Breast Cancer Res Treat; 2023 Aug; 200(3):337-346. PubMed ID: 37266756
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term outcome in young women with breast cancer: a population-based study.
    Fredholm H; Magnusson K; Lindström LS; Garmo H; Fält SE; Lindman H; Bergh J; Holmberg L; Pontén F; Frisell J; Fredriksson I
    Breast Cancer Res Treat; 2016 Nov; 160(1):131-143. PubMed ID: 27624330
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
    Prat A; Cheang MC; Galván P; Nuciforo P; Paré L; Adamo B; Muñoz M; Viladot M; Press MF; Gagnon R; Ellis C; Johnston S
    JAMA Oncol; 2016 Oct; 2(10):1287-1294. PubMed ID: 27281556
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of age, intrinsic subtype and local treatment on long-term local-regional recurrence and breast cancer mortality among low-risk breast cancer patients.
    Laurberg T; Alsner J; Tramm T; Jensen V; Lyngholm CD; Christiansen PM; Overgaard J
    Acta Oncol; 2017 Jan; 56(1):59-67. PubMed ID: 27846764
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Value of a gene signature assay in patients with early breast cancer and intermediate risk: a single institution retrospective study.
    Bonneterre J; Prat A; Galván P; Morel P; Giard S
    Curr Med Res Opin; 2016 May; 32(5):835-9. PubMed ID: 26809116
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
    Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
    Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance.
    Kim HK; Park KH; Kim Y; Park SE; Lee HS; Lim SW; Cho JH; Kim JY; Lee JE; Ahn JS; Im YH; Yu JH; Park YH
    Cancer Res Treat; 2019 Apr; 51(2):737-747. PubMed ID: 30189722
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.
    Nitz U; Gluz O; Christgen M; Kates RE; Clemens M; Malter W; Nuding B; Aktas B; Kuemmel S; Reimer T; Stefek A; Lorenz-Salehi F; Krabisch P; Just M; Augustin D; Liedtke C; Chao C; Shak S; Wuerstlein R; Kreipe HH; Harbeck N
    Breast Cancer Res Treat; 2017 Oct; 165(3):573-583. PubMed ID: 28664507
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study.
    Sanpaolo P; Barbieri V; Genovesi D
    Eur J Surg Oncol; 2011 Oct; 37(10):876-82. PubMed ID: 21824742
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bcl-2 is a highly significant prognostic marker of hormone-receptor-positive, human epidermal growth factor receptor-2-negative breast cancer.
    Seong MK; Lee JY; Byeon J; Sohn YJ; Seol H; Lee JK; Kim EK; Kim HA; Noh WC
    Breast Cancer Res Treat; 2015 Feb; 150(1):141-8. PubMed ID: 25682076
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined analysis of vascular invasion, grade, HER2 and Ki67 expression identifies early breast cancer patients with questionable benefit of systemic adjuvant therapy.
    Synnestvedt M; Borgen E; Russnes HG; Kumar NT; Schlichting E; Giercksky KE; Kåresen R; Nesland JM; Naume B
    Acta Oncol; 2013 Jan; 52(1):91-101. PubMed ID: 22934555
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy.
    Laible M; Hartmann K; Gürtler C; Anzeneder T; Wirtz R; Weber S; Keller T; Sahin U; Rees M; Ramaswamy A
    BMC Cancer; 2019 Jul; 19(1):694. PubMed ID: 31307414
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PAM50- and immunohistochemistry-based subtypes of breast cancer and their relationship with breast cancer mortality in a population-based study.
    Wang L; Li Q; Aushev VN; Neugut AI; Santella RM; Teitelbaum S; Chen J
    Breast Cancer; 2021 Nov; 28(6):1235-1242. PubMed ID: 34003448
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intrinsic subtypes and genomic signatures of primary breast cancer and prognosis after systemic relapse.
    Falato C; Tobin NP; Lorent J; Lindström LS; Bergh J; Foukakis T
    Mol Oncol; 2016 Apr; 10(4):517-25. PubMed ID: 26651914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
    Sestak I; Buus R; Cuzick J; Dubsky P; Kronenwett R; Denkert C; Ferree S; Sgroi D; Schnabel C; Baehner FL; Mallon E; Dowsett M
    JAMA Oncol; 2018 Apr; 4(4):545-553. PubMed ID: 29450494
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score.
    Sestak I; Cuzick J; Dowsett M; Lopez-Knowles E; Filipits M; Dubsky P; Cowens JW; Ferree S; Schaper C; Fesl C; Gnant M
    J Clin Oncol; 2015 Mar; 33(8):916-22. PubMed ID: 25332252
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen.
    Chia SK; Bramwell VH; Tu D; Shepherd LE; Jiang S; Vickery T; Mardis E; Leung S; Ung K; Pritchard KI; Parker JS; Bernard PS; Perou CM; Ellis MJ; Nielsen TO
    Clin Cancer Res; 2012 Aug; 18(16):4465-72. PubMed ID: 22711706
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of pathologic response and long-term outcome in locally advanced breast cancers after neoadjuvant chemotherapy: comparison of pathologic classification systems.
    Choi M; Park YH; Ahn JS; Im YH; Nam SJ; Cho SY; Cho EY
    Breast Cancer Res Treat; 2016 Dec; 160(3):475-489. PubMed ID: 27730423
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic Value of a BCSC-associated MicroRNA Signature in Hormone Receptor-Positive HER2-Negative Breast Cancer.
    Gong C; Tan W; Chen K; You N; Zhu S; Liang G; Xie X; Li Q; Zeng Y; Ouyang N; Li Z; Zeng M; Zhuang S; Lau WY; Liu Q; Yin D; Wang X; Su F; Song E
    EBioMedicine; 2016 Sep; 11():199-209. PubMed ID: 27566954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 63.